The Global Health Body Sounds Concern Over Severe Lack of Obesity Medications
Less than a tenth of patients that would benefit from obesity jabs like Wegovy have access to them, states the WHO as it releases its initial recommendations on the therapies.
With over a billion people worldwide currently classified as obese, it is calling for more widespread and fairer access to GLP-1 medication.
Based on forecasts, more than two billion are projected to be living with obesity by 2030 without intervention.
"The latest guidance recognises that obesity is a lifelong illness that can be managed with holistic and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major barriers to universal availability to the jabs that can help people shift substantial body mass, explains the body.
Skinny Jab Supply Crisis
Despite the present best projected case, the manufacturing of GLP-1 therapies might only reach about 100 million people – under 10% of those who need them, per the health organization.
The advice calls on governments and firms to expand access, by strategies such as voluntary licensing.
The intellectual property rights on a key compound – the core component of a leading brand – is set to lapse in multiple nations in 2026.
How Weight-Loss Jabs Work
These medications mimick a natural hormone to reduce digestion speed, curb appetite and increase satiety so individuals eat less.
Patients typically start to lose weight in the initial weeks of beginning the regular doses.
Evidence suggests patients may put most of the weight back on a year later of discontinuing the drug, as their typical food cravings return.
Being carrying excess weight increases your risk for developing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity affects people in all nations and was linked to over three and a half million deaths worldwide in 2024, per the health agency.